Clinical Trials · NCT05050942
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Camurus AB
- Enrollment
- 332
- Start date
- Oct 2021
- Locations
- 86 sites, 12 countries
- Primary endpoint
- Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)